Pharmaceuticals

Sputnik V demonstrates strong protection against Omicron variant, with over 2 times higher virus neutralizing activity compared to the Pfizer vaccine according to a unique independent comparative study conducted by the Spallanzani Institute in Italy

Previous studies also demonstrated additional significant strengthening of protection against Omicron by Sputnik Light booster, which can also be a universal booster to other vaccines to strengthen and lengthen their protection against Omicron. MOSCOW, Jan. 20, 2022 /PRNewswire/ -- * A uniqu...

2022-01-20 19:00 5658

Successful Completion of First Patient Implantation of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in China Announced by Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI

CATANIA, Italy, Jan. 20, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered inItaly, is pleased to divulge the successful completion of the first patient implantation of MINI WELL® and MINI WELL TORIC® IOLs inChina, announced via Affamed Technologies, Joint Ventur...

2022-01-20 16:00 3897

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris (TM) Nasal Spray in Singapore, Hong Kong and Vietnam

* Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory approvals) across these markets. * Glenmark will recei...

2022-01-20 15:48 3451

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inThailand * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3265

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inIndonesia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3599

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inPhilippines * High scores in values, ethics and integrity serve as a driver for a strong...

2022-01-20 08:00 2984

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the second consecutive year for the certification inAustralia & New Zealand * High scores in values, ethics and integrity serve as a driver ...

2022-01-20 08:00 2895

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inMalaysia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 2920

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fifth consecutive year for the certification inSingapore * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 2621

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inVietnam * High scores in values, ethics and integrity serve as a driver for a strong cor...

2022-01-20 08:00 6512

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Genesis Prize Chairman highlights immense role of Jewish scientists and doctors in combatting the pandemic: "A very proud moment for the entire Jewish community" JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr.Albert Bourla, Chairman and CEO of Pfizer,...

2022-01-20 06:13 2574

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...

2022-01-19 20:00 2708

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization  (CRO-CDMO), today announced the app...

2022-01-19 18:30 4448

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...

2022-01-19 09:00 10115

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner * Surviv...

2022-01-19 08:05 4434

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondyli...

2022-01-19 08:00 4264

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...

2022-01-18 20:00 2664

Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos

HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX: 1672) today announces signing of the ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export Co., Ltd (as buyer) ofLaos and Ascletis Pharmaceuticals Co., Ltd. (as seller), ...

2022-01-18 18:00 3737

Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials

WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ -- Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formedDelaware -based pharmaceutical development company, and the signing of aUSD 1...

2022-01-18 17:00 2862

Baheya Foundation, Egypt's Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening

SEOUL, South Korea, Jan. 18, 2022 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with Baheya Foundation for Early Detection & Treatment of Breast Cancer, a non-profit organization based inEgypt that treats women with breast cancer. According to the agreement, the foundation will...

2022-01-18 13:00 2434
1 ... 164165166167168169170 ... 184